Skip to main content
Patient Care

FDA Approves Adapt Pharma's NARCAN Nasal Spray 2mg

DUBLIN, Jan. 25, 2017 /PRNewswire/ -- Today, the U.S. Food and Drug Administration (FDA) approved NARCAN® Nasal Spray as a 2mg formulation for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. The 2mg dose is approved for use in opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts.

This approval comes just over one year after the FDA approved the first-of-its-kind, ready-to-use, needle-free version of naloxone, NARCAN® Nasal Spray 4mg, which has been commercially available since February 2016 following expedited FDA review and approval.

NARCAN® Nasal Spray 2mg and 4mg are concentrated naloxone nasal sprays providing ready-to-use emergency treatments of opioid overdose, including prescription opioid painkiller-, fentanyl-, carfentanil- and heroin-related overdose. NARCAN® Nasal Spray is not a substitute for emergency medical care.

ABOUT ADAPT PHARMA

Adapt Pharma is a privately-held pharmaceutical company committed to positively impacting the lives of patients. Adapt Pharma's strategy is to identify, evaluate, selectively acquire and enhance the value of late stage development, and FDA approved, pharmaceutical products. Adapt Pharma's company headquarters is in Dublin, Ireland and its U.S. headquarters is in Radnor, Pennsylvania. For more information, please visit www.adaptpharma.com.

Back to Top